Like_老虎社区_美港股上老虎

yl2021
2021-12-22

Valneva Posts Positive Lot-to-Lot Consistency Data For Its Single-Dose Chikungunya Vaccine<blockquote>Valneva公布了其单剂基孔肯雅热疫苗的积极批次间一致性数据</blockquote>

Valneva SE announced topline results from the lot-to-lot Phase 3 trial of its single-shot chikunguny

Valneva Posts Positive Lot-to-Lot Consistency Data For Its Single-Dose Chikungunya Vaccine<blockquote>Valneva公布了其单剂基孔肯雅热疫苗的积极批次间一致性数据</blockquote>

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":691840359,"tweetId":"691840359","gmtCreate":1640172952730,"gmtModify":1640173549737,"author":{"id":3576231438371359,"idStr":"3576231438371359","authorId":3576231438371359,"authorIdStr":"3576231438371359","name":"yl2021","avatar":"https://static.tigerbbs.com/9130003d93212acf586123bc8fe8a1e0","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":115,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Like</p></body></html>","htmlText":"<html><head></head><body><p>Like</p></body></html>","text":"Like","highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/691840359","repostId":1176786115,"repostType":4,"repost":{"id":"1176786115","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1640172243,"share":"https://www.laohu8.com/m/news/1176786115?lang=zh_CN&edition=full","pubTime":"2021-12-22 19:24","market":"us","language":"en","title":"Valneva Posts Positive Lot-to-Lot Consistency Data For Its Single-Dose Chikungunya Vaccine<blockquote>Valneva公布了其单剂基孔肯雅热疫苗的积极批次间一致性数据</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1176786115","media":"Benzinga","summary":"Valneva SE announced topline results from the lot-to-lot Phase 3 trial of its single-shot chikunguny","content":"<p><b>Valneva SE</b>&nbsp;announced topline results&nbsp;from the lot-to-lot Phase 3 trial of its single-shot chikungunya vaccine candidate, VLA1553.</p><p><blockquote><b>瓦尔内瓦</b>公布了其单剂基孔肯雅热候选疫苗VLA1553的批对批3期试验的主要结果。</blockquote></p><p> <ul>  <li>The trial met its primary endpoint, demonstrating that three consecutively manufactured vaccine lots elicited equivalent immune responses on Day 29 after vaccination.</li>  <li>Lot-to-lot trials demonstrate manufacturing consistency, one of the standard requirements for vaccine licensure.</li>  <li>The trial, which included 408 participants aged 18 to 45 years, confirmed the favorable immunogenicity profile demonstrated in the pivotal Phase 3 trial.</li>  <li>All three lots were equally well-tolerated, and the safety profile was consistent with the pivotal Phase 3 trial results.</li>  <li>The lot-to-lot data will be part of its submission with the FDA expected to start in 2022.</li>  <li>The lot-to-lot trial will continue towards the final six-month analysis, with final trial results expected in Q2 of 2022.</li>  <li>Chikungunya is a mosquito-borne viral disease.</li>  <li>VLA1553 is a live-attenuated, single-dose vaccine candidate targeting the chikungunya virus. It has been designed by deleting a part of the chikungunya virus genome.</li>  <li><b>Price Action:</b>&nbsp;VLAN shares are closed at $57.39 on Tuesday.</li> </ul></p><p><blockquote><ul><li>该试验达到了其主要终点，证明三个连续生产的疫苗批次在接种后第29天引发了等效的免疫应答。</li><li>批间试验证明了生产一致性，这是疫苗许可的标准要求之一。</li><li>该试验包括408名年龄在18至45岁之间的参与者，证实了关键3期试验中证明的良好免疫原性特征。</li><li>所有三个批次的耐受性同样良好，安全性特征与关键的3期试验结果一致。</li><li>批次间数据将成为其向FDA提交的一部分，预计将于2022年开始。</li><li>批次间试验将继续进行最终的六个月分析，最终试验结果预计将于2022年第二季度公布。</li><li>基孔肯雅热病是一种由蚊子传播的病毒性疾病。</li><li>VLA1553是一种针对基孔肯雅热病毒的减毒单剂量候选疫苗。它是通过删除基孔肯雅热病毒基因组的一部分而设计的。</li><li><b>价格走势：</b>VLAN股价周二收于57.39美元。</li></ul></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Valneva Posts Positive Lot-to-Lot Consistency Data For Its Single-Dose Chikungunya Vaccine<blockquote>Valneva公布了其单剂基孔肯雅热疫苗的积极批次间一致性数据</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nValneva Posts Positive Lot-to-Lot Consistency Data For Its Single-Dose Chikungunya Vaccine<blockquote>Valneva公布了其单剂基孔肯雅热疫苗的积极批次间一致性数据</blockquote>\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time smaller\">2021-12-22 19:24</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<p><b>Valneva SE</b>&nbsp;announced topline results&nbsp;from the lot-to-lot Phase 3 trial of its single-shot chikungunya vaccine candidate, VLA1553.</p><p><blockquote><b>瓦尔内瓦</b>公布了其单剂基孔肯雅热候选疫苗VLA1553的批对批3期试验的主要结果。</blockquote></p><p> <ul>  <li>The trial met its primary endpoint, demonstrating that three consecutively manufactured vaccine lots elicited equivalent immune responses on Day 29 after vaccination.</li>  <li>Lot-to-lot trials demonstrate manufacturing consistency, one of the standard requirements for vaccine licensure.</li>  <li>The trial, which included 408 participants aged 18 to 45 years, confirmed the favorable immunogenicity profile demonstrated in the pivotal Phase 3 trial.</li>  <li>All three lots were equally well-tolerated, and the safety profile was consistent with the pivotal Phase 3 trial results.</li>  <li>The lot-to-lot data will be part of its submission with the FDA expected to start in 2022.</li>  <li>The lot-to-lot trial will continue towards the final six-month analysis, with final trial results expected in Q2 of 2022.</li>  <li>Chikungunya is a mosquito-borne viral disease.</li>  <li>VLA1553 is a live-attenuated, single-dose vaccine candidate targeting the chikungunya virus. It has been designed by deleting a part of the chikungunya virus genome.</li>  <li><b>Price Action:</b>&nbsp;VLAN shares are closed at $57.39 on Tuesday.</li> </ul></p><p><blockquote><ul><li>该试验达到了其主要终点，证明三个连续生产的疫苗批次在接种后第29天引发了等效的免疫应答。</li><li>批间试验证明了生产一致性，这是疫苗许可的标准要求之一。</li><li>该试验包括408名年龄在18至45岁之间的参与者，证实了关键3期试验中证明的良好免疫原性特征。</li><li>所有三个批次的耐受性同样良好，安全性特征与关键的3期试验结果一致。</li><li>批次间数据将成为其向FDA提交的一部分，预计将于2022年开始。</li><li>批次间试验将继续进行最终的六个月分析，最终试验结果预计将于2022年第二季度公布。</li><li>基孔肯雅热病是一种由蚊子传播的病毒性疾病。</li><li>VLA1553是一种针对基孔肯雅热病毒的减毒单剂量候选疫苗。它是通过删除基孔肯雅热病毒基因组的一部分而设计的。</li><li><b>价格走势：</b>VLAN股价周二收于57.39美元。</li></ul></blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VALN":"Valneva SE"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1176786115","content_text":"Valneva SE announced topline results from the lot-to-lot Phase 3 trial of its single-shot chikungunya vaccine candidate, VLA1553.\n\nThe trial met its primary endpoint, demonstrating that three consecutively manufactured vaccine lots elicited equivalent immune responses on Day 29 after vaccination.\nLot-to-lot trials demonstrate manufacturing consistency, one of the standard requirements for vaccine licensure.\nThe trial, which included 408 participants aged 18 to 45 years, confirmed the favorable immunogenicity profile demonstrated in the pivotal Phase 3 trial.\nAll three lots were equally well-tolerated, and the safety profile was consistent with the pivotal Phase 3 trial results.\nThe lot-to-lot data will be part of its submission with the FDA expected to start in 2022.\nThe lot-to-lot trial will continue towards the final six-month analysis, with final trial results expected in Q2 of 2022.\nChikungunya is a mosquito-borne viral disease.\nVLA1553 is a live-attenuated, single-dose vaccine candidate targeting the chikungunya virus. It has been designed by deleting a part of the chikungunya virus genome.\nPrice Action: VLAN shares are closed at $57.39 on Tuesday.","news_type":1,"symbols_score_info":{"VALN":0.9}},"isVote":1,"tweetType":1,"viewCount":2338,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":4,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}